论文部分内容阅读
目的观察周剂量多西他赛结合低剂量顺铂治疗高龄患者晚期非小细胞肺癌(NSCLC)的临床疗效。方法选择2013年1月至2014年2月晚期高龄NSCLC患者104例,将其随机分为观察组和对照组,每组52例,观察组给予周剂量多西他赛结合低剂量顺铂方案,对照组给予周剂量多西他赛结合低剂量奥沙利铂方案,观察比较两组的疗效、不良反应及生存情况。结果观察组总有效率(59.6%)与对照组(57.6%)比较差异未见统计学意义(P>0.05)。两组患者血红蛋白下降(63.5%比57.6%)、肾功能异常(23.1%比26.9%)、脱发(25.0%比30.8%)、恶心呕吐(48.1%比42.3%)、腹泻(11.5%比7.7%)发生率间比较差异未见统计学意义(P>0.05);观察组白细胞下降(61.5%)、肝功能异常(19.2%)发生率均显著低于对照组(78.8%、40.4%),差异有统计学意义(P<0.05);血小板下降(55.7%)的发生率显著高于对照组(34.6%),差异有统计学意义(P<0.05)。两组患者的生存情况:观察组1年生存率(51.9%)、2年生存率(23.1%)与对照组(53.8%、21.2%)比较差异未见统计学意义(P>0.05)。结论周剂量多西他赛结合低剂量顺铂治疗高龄患者晚期非小细胞肺癌有较好的临床疗效,与周剂量多西他赛结合低剂量奥沙利铂治疗效果相似,且两方案的不良反应较轻,患者1年生存率尚可,2年生存率较低。
Objective To observe the clinical efficacy of weekly doses of docetaxel combined with low-dose cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients. Methods 104 patients with advanced NSCLC from January 2013 to February 2014 were randomly divided into observation group and control group with 52 cases in each group. The observation group was given weekly docetaxel combined with low-dose cisplatin regimen, The control group was given weekly doses of docetaxel combined with low-dose oxaliplatin. The curative effect, adverse reactions and survival of the two groups were observed and compared. Results The total effective rate (59.6%) in the observation group was not significantly different from that in the control group (57.6%) (P> 0.05). Hemoglobin (63.5% vs. 57.6%), renal dysfunction (23.1% vs. 26.9%), hair loss (25.0% vs. 30.8%), nausea and vomiting (48.1% vs. 42.3%) and diarrhea (11.5% vs. 7.7% ) (P> 0.05). The incidences of leukopenia (61.5%) and abnormal liver function (19.2%) in the observation group were significantly lower than those in the control group (78.8%, 40.4%), and the difference was not statistically significant (P <0.05). The incidence of thrombocytopenia (55.7%) was significantly higher than that of the control group (34.6%), the difference was statistically significant (P <0.05). Survival status of two groups of patients: The 1-year survival rate (51.9%), 2-year survival rate (23.1%) in the observation group and the control group (53.8%, 21.2%) showed no significant difference (P> 0.05). Conclusion Weekdose docetaxel combined with low-dose cisplatin in elderly patients with advanced non-small cell lung cancer has a good clinical efficacy, and week dose docetaxel combined with low-dose oxaliplatin treatment is similar, and the two programs are not good The reaction is mild, the patient’s 1-year survival rate is acceptable, 2-year survival rate is lower.